1. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial. Issue 3 (8th April 2019) Authors: Schiffmann, Raphael; Goker‐Alpan, Ozlem; Holida, Myrl; Giraldo, Pilar; Barisoni, Laura; Colvin, Robert B.; Jennette, Charles J.; Maegawa, Gustavo; Boyadjiev, Simeon A.; Gonzalez, Derlis; Nicholls, Kathy; Tuffaha, Ahmad; Atta, Mohamed G.; Rup, Bonita; Charney, Martha R.; Paz, Alona; Szlaifer, Mali... Journal: Journal of inherited metabolic disease Issue: Volume 42:Issue 3(2019) Page Start: 534 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗